register

News & Trends - Pharmaceuticals

TGA to permit conditional substitution to ease serious shortages

Health Industry Hub | April 27, 2020 |

Pharma News: In response to the COVID-19 pandemic, the Therapeutic Goods Administration (TGA) is implementing Serious Shortage Medicine Substitution Notices.

These notices will allow pharmacists to substitute dose strengths, forms and different release-rate forms of specified medicines under certain conditions without prior approval from the prescribing doctor. Substituting medicines in this way will relieve pressure on doctors and allow continued supply of essential medicines for patients.

The TGA has been working closely with health professional peak organisations, state and territory governments and other key stakeholders to urgently develop measures to help ease serious medicine shortages during the COVID-19 pandemic.

Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

The COVID-19 pandemic has seen unprecedented increases in demand for certain medicines. Together with disruptions to manufacturing and logistical operations globally, the increased demand has put pressure on supplies of a number of medicines that Australians rely on for their ongoing health and wellbeing.

Although few products to date have been the subject of national-level shortages, local-level supply disruptions have made it more difficult for some people to obtain their regular medicines.

Serious shortages are normally defined as verified shortages of a particular medicine at a national level. However, the new substitution arrangements may be used to address severe local-level supply disruptions during the COVID-19 pandemic. Serious shortages will be characterised by a high likelihood of significant and immediate negative health consequences for patients who cannot access the medicine at the prescribed intervals.

The changes will allow a pharmacist to dispense different strengths of a product (such as two 20 mg tablets in place of a 40 mg tablet), or a different dose form of the same medicine (such as a capsule instead of a tablet) or a different release formulations (such as extended release instead of immediate release).

Substitution of a medicine with another product containing a different active ingredient will not be permitted under these measures.

You may also like PRIME Awards 2020 call for entries – the only awards program dedicated to recognising excellence within Australian healthcare communications, is now open for entries.


News & Trends - MedTech & Diagnostics

Medtronic partners with local researchers in stroke trial

Medtronic partners with local researchers in stroke trial

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: Endovascular thrombectomy has been shown to be more effective in reducing disability than medical therapy alone […]

More


News & Trends - Pharmaceuticals

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Industry Hub | March 1, 2024 |

Pharma News: Mark Butler MP, Federal Minister for Health, and Senator Anne Ruston, Shadow Minister for Health, reflected on the […]

More


News & Trends - Pharmaceuticals

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Health Industry Hub | March 1, 2024 |

Pharma News: Gilead has applied to the Medical Services Advisory Committee (MSAC) for funding of its cutting-edge CAR T-cell therapy, […]

More


News & Trends - MedTech & Diagnostics

Should private insurers face scrutiny for soaring profits while patients foot the bill? MTAA, Private Healthcare Australia

Should private health insurers face scrutiny for soaring profits while patients foot the bill?

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: In a clash of interests, the Medical Technology Association of Australia (MTAA) has once again urged […]

More


This content is copyright protected. Please subscribe to gain access.